If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...

Artificial intelligence tools are increasingly being developed to predict cancer biology directly from microscope images, ...

Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...

Research from the University of Warwick suggests that many AI systems may be using visual shortcuts rather than true biology, ...

US FDA grants full approval to Pfizer’s Braftovi combination regimen in first-line metastatic colorectal cancer: New York Thursday, February 26, 2026, 12:00 Hrs [IST] Pfizer Inc ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

University of Warwick research warns that popular deep learning systems trained for cancer pathology may be relying on hidden ...

Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored ...

Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...

New research warns that popular deep learning systems trained for cancer pathology may be relying on hidden shortcuts rather than genuine biological signals. Artificial intelligence tools are ...

When the performance of AI models was assessed within stratified patient subgroups, such as only high-grade breast cancers or only MSI-positive tumors, accuracy fell substantially, revealing that the ...